HC Wainwright Issues Negative Estimate for Humacyte Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($1.36) per share for the year, down from their previous estimate of ($1.28). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04).

HUMA has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Benchmark restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. TD Cowen restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $11.00.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $4.84 on Friday. The firm has a 50 day moving average of $5.43 and a 200-day moving average of $6.16. Humacyte has a 12 month low of $2.35 and a 12 month high of $9.97. The company has a current ratio of 1.10, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $577.06 million, a PE ratio of -3.61 and a beta of 1.47.

Insider Activity

In related news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now owns 3,677,262 shares in the company, valued at $23,350,613.70. The trade was a 8.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,084,153 shares of company stock valued at $6,869,996. Insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. nVerses Capital LLC bought a new stake in Humacyte in the second quarter worth approximately $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte during the third quarter worth $75,000. Principal Financial Group Inc. acquired a new stake in Humacyte in the second quarter worth $83,000. FORA Capital LLC bought a new stake in Humacyte in the third quarter valued at $96,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte during the second quarter valued at about $97,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.